News and Trends 10 Oct 2014
How Gilead’s Hepatitis C Treatment challenges European Public Health Systems
American Biotech company Gilead is selling its new drug Sovaldi since 2013, which brings significant breakthrough in Hepatitis C treatment. The high cost of the drug, up to €100 000, is a challenge for european Public Health system which tries to lower its overall cost for their public health system. Hepatitis C is an infectious disease […]